CNS penetrant small molecule pan-histone deacetylase (HDAC) inhibitor designed to treat progressive neurofibromatosis type 2 (NF2)-mutated meningiomas The program halts will shrink Recursion’s ...

(RTTNews) - Recursion Pharmaceuticals, Inc. (RXRX), a clinical-stage TechBio company, on Monday, announced that it is deprioritizing three of its clinical programs and one preclinical program ...

which is a good thing because there is little prospect of Recursion delivering any drug approvals within the next three years, given its most advanced program has only reached the Phase 1/2 stage.

is the first designed to be reversible and CNS penetrant for small-cell lung cancer Recursion also announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new ...